Through the UpSet analysis, we identified 296 PRAD patients (60%) with simultaneous heightened ESR1 and MMP3 at the time of the primary treatment, which significantly correlated with worse BCR-free survival. The gene discussed is ESR1; the disease is prostate adenocarcinoma.